The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | OMNIVERSE: safety and tolerability of oral azacitidine plus venetoclax in patients with AML
Shaun Fleming, MBBS, FRACP, FRCPA, Alfred Hospital, Melbourne, Australia, comments on the rationale and results of the Phase Ib OMNIVERSE (NCT04887857) study evaluating the safety and tolerability of oral azacitidine plus venetoclax in patients with acute myeloid leukemia (AML). The study reported a manageable safety profile for this combination, with evidence of clinical responses. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen – research funding, speakers honoraria, advisory board membership
Gilead – advisory board membership
Novartis – speakers honorarium
BMS – advisory board membership, speakers honorarium
Pfizer – advisory board membership, speakers honorarium
